Researchers now found a new method that is capable to identify splicing biomarkers for living cancer. The researchers are also taking it helpful for identifying other types of cancer. The study channelized by Cold Spring Harbor Laboratory now developed a method that can identify splicing-based biomarkers for the liver cancer, called hepatocellular carcinoma (HCC). Professor Adrian Krainer who channeled this research also believes that this will be helpful to identify other forms of cancer as well.
Liver cancer is generally a common form of cancer and is diverse to many people, hence it gets difficult for the officials to predict it much before and to fight with it in the same way. Krainer tells,”This study underscores the potential for learning how RNA splicing variants can contribute to cancer and points to these variants as potential biomarkers for cancer progression.” Spicing is a method in which RNA message is copied by the information coded in a gene and is edited before it can serve as a blueprint.
The researchers tell that a gene can give way to multiple RNA messages in which each can result in different protein variant known as “Isoform”. It is also updated that this splitting of RNA creates many errors and variations for a number of diseases. These errors in splicing can give way to some non-functional proteins with different functions.
The recent study tells that this splicing irregularity of the cancer cells in the liver. “If we can do this, AFMID splicing can become a therapeutic target and the source of a new drug for liver cancer,” Lin tells. The team thinks to use those small molecules known as ASOs (Antisense Oligonucleotides) that nullifies the RNA to change the way AFMID’s RNA message that gets spliced. These findings are calling to be effective for detecting liver cancer at an early stage.